If you are weighing up Foundayo vs Mounjaro, the core difference is simple to state: Foundayo (orforglipron) is a once-daily tablet, while Mounjaro (tirzepatide) is a weekly injection. But the two medicines also differ in how they work at the receptor level, and that shapes what to expect. This article compares them calmly, without hype in either direction.
This is information only, not medical advice. Both are prescription-only medicines, and a qualified prescriber is the person who decides whether any treatment is suitable for you.
Foundayo vs Mounjaro: the essentials at a glance
Both medicines belong to the broad family of incretin-based treatments — drugs that mimic hormones your gut releases after eating. Where they part company is in their chemistry and their delivery.
- Foundayo (orforglipron) — a non-peptide, small-molecule GLP-1 receptor agonist, designed to be swallowed as a daily tablet.
- Mounjaro (tirzepatide) — a peptide that activates both the GLP-1 and GIP receptors, given as a once-weekly injection.
To understand the tablet's design in more depth, see our companion article on how orforglipron works.
How each one works in the body
GLP-1 (glucagon-like peptide-1) is a hormone released after meals. It prompts the pancreas to release insulin when blood sugar rises, slows how fast the stomach empties, and acts on appetite centres in the brain so you feel full sooner. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that also influences insulin and fat metabolism.
Mounjaro: a dual-receptor peptide
Tirzepatide activates both the GLP-1 and GIP receptors — this is why it is often described as a "dual agonist". Because it is a peptide (a small protein-like chain of amino acids), it would be broken down in the gut if swallowed, so it is injected under the skin once a week.
Foundayo: a single-receptor tablet
Orforglipron targets only the GLP-1 receptor, similar to semaglutide. Crucially, it is a small molecule made by chemical synthesis rather than a peptide, so it can survive digestion and be absorbed as a tablet — without the strict fasting rules that oral semaglutide requires. That is the headline appeal of the Foundayo vs Mounjaro comparison: a genuinely convenient oral option for people who dislike injections.
What the trial evidence suggests
Trial results are the fairest way to compare medicines, but you have to be careful comparing across different studies with different participants and durations.
For context, tirzepatide's SURMOUNT-1 trial produced average weight loss of around 21% at the top dose over roughly 72 weeks alongside lifestyle changes — among the strongest results seen for a weight-management medicine. Semaglutide 2.4 mg, a single GLP-1 agonist like orforglipron, produced around 15% in the STEP 1 trial.
Because orforglipron acts on the GLP-1 receptor only, its results are more likely to sit in the range of single-agonist medicines than the dual-agonist Mounjaro — but the full picture depends on the complete trial dataset and regulatory review. We keep a general summary on our home page and track the research on our development page. Beware of anyone quoting precise head-to-head figures as if the two had been tested directly against each other in the same trial.
Tablet vs injection: the practical differences
For many people, the day-to-day experience matters as much as the numbers.
- Route: Foundayo is a daily tablet; Mounjaro is a weekly injection using a pre-filled pen.
- Frequency: Once daily versus once weekly. Some prefer the routine of a daily pill; others prefer a single weekly jab.
- Storage: Injectable pens typically have cold-chain and refrigeration considerations; a tablet is generally simpler to store and travel with.
- Needle comfort: A tablet removes the injection barrier entirely, which for some people is the deciding factor.
None of these points make one medicine "better" — they make one or the other more suitable for a given person, which is exactly the kind of judgement a prescriber is there to make.
Side effects: a familiar pattern
Because both medicines act on GLP-1 signalling, their side-effect profiles overlap. The most common effects are gastrointestinal — nausea, vomiting, diarrhoea and constipation — and they are usually most noticeable when a dose is first started or stepped up. Slowing the stomach is part of how these medicines curb appetite, so the gut naturally feels the effect too.
Prescribers generally start at a low dose and increase gradually to help the body adjust. You can read more on our side effects page and about the step-up approach on our dosage page. If you experience a side effect from any medicine, you can report it through the MHRA Yellow Card scheme.
Where does UK availability stand?
This is an important part of the Foundayo vs Mounjaro question. Mounjaro is already licensed in the UK and available through the NHS for certain uses as well as via regulated private providers. Foundayo (orforglipron) is newer, and its route through MHRA review and any NICE assessment is still developing — so it is not something you can simply pick up today in the way Mounjaro can be prescribed.
We track the latest position on our UK availability page. Whichever medicine is discussed, any legitimate UK supply comes through GPhC-registered pharmacies and CQC-regulated clinics after a prescriber assessment. Avoid websites offering GLP-1 medicines — or "compounded" versions — without a prescription; these fall outside UK regulation and carry real safety risks.
A note on cost
Private prices for GLP-1 treatments vary between regulated providers and change over time. We do not quote prices or name sellers. If cost is a factor, compare regulated UK providers carefully and discuss options with a prescriber or pharmacist.
Frequently asked questions
Is Foundayo the same as Mounjaro?
No. Foundayo (orforglipron) is a once-daily tablet that activates the GLP-1 receptor only. Mounjaro (tirzepatide) is a weekly injection that activates both the GLP-1 and GIP receptors. They are related but chemically and pharmacologically different.
Which causes more weight loss, Foundayo or Mounjaro?
There is no direct head-to-head trial. In separate studies, the dual-agonist tirzepatide produced very high average weight loss, while single GLP-1 agonists tend to produce somewhat less. The full evidence for orforglipron is still being assessed, so precise comparisons should be treated with caution.
Can I get Foundayo in the UK now?
Not routinely. Orforglipron is still working through the regulatory process. Mounjaro is already licensed. See our UK availability page for the current position.
Do they have the same side effects?
Because both act on GLP-1 signalling, they share a similar pattern — mostly gastrointestinal effects such as nausea, especially when starting or increasing a dose. Report any side effects via the MHRA Yellow Card scheme.
Is a tablet better than an injection?
Neither is universally better. A tablet suits people who dislike needles or want simpler storage; an injection suits those who prefer a single weekly dose. Suitability depends on your circumstances and a prescriber's assessment.
Is this article medical advice?
No. This is general information only. Both medicines are prescription-only, and a qualified prescriber decides what is appropriate for you. See our FAQ page for more.